Physician profile
Candis S Davis
NPI 1679987804
$7,415.46
in general payments reported to CMS, 2019-2025
20 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $832 · 2023: $1,562 · 2024: $2,132 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,305 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,304.80 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,438.03 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $946.37 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $630.28 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $628.56 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $532.29 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $526.58 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $516.13 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $496.02 | 2021-2025 | |
| Genzyme Corporation | $470.33 | 2021-2025 | |
| Leo Pharma INC. | $327.36 | 2021-2025 | Adbry, Anzupgo |
| Biofrontera INC. | $217.35 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $165.72 | 2024-2025 | Affinity |
| Novartis Pharmaceuticals Corporation | $157.35 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $118.95 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $112.32 | 2024 | Vtama |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.41 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $40.83 | 2024-2025 | Aklief, Oracea, Nemluvio |
| Almirall LLC | $19.03 | 2023 | Klisyri |
| Arcutis Biotherapeutics, INC. | $17.31 | 2023 | |
| Dermira, INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candis Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.